Jump to main content
Jump to site search

Issue 6, 2017
Previous Article Next Article

Maltodextrin modified liposomes for drug delivery through the blood–brain barrier

Author affiliations

Abstract

Central nervous system acting drugs, when administered intravenously, cannot show their effect in the brain due to the difficulty in crossing the blood–brain barrier (BBB). Levodopa is one of those drugs that are used to treat Parkinson's disease. In this study, a new liposomal levodopa delivery system that is modified with maltodextrin was developed in order to target and enhance transport through the BBB. An antioxidant, glutathione, was co-loaded in liposomes as a supportive agent and its effect on liposome stability and delivery was investigated. Glutathione co-loading had a positive effect on the viabilities of 3T3 and SH-SY5Y cells. Maltodextrin targeted liposomes showed high in vitro levodopa passage in the parallel artificial membrane permeability assay and had superior binding to MDCK cells. Results suggest that maltodextrin modification of liposomes is an effective way of targeting the BBB and the developed liposomal formulation would improve brain delivery of central nervous system agents.

Graphical abstract: Maltodextrin modified liposomes for drug delivery through the blood–brain barrier

Back to tab navigation

Supplementary files

Publication details

The article was received on 26 Jan 2017, accepted on 05 May 2017 and first published on 05 May 2017


Article type: Research Article
DOI: 10.1039/C7MD00045F
Citation: Med. Chem. Commun., 2017,8, 1337-1345
  •   Request permissions

    Maltodextrin modified liposomes for drug delivery through the blood–brain barrier

    Z. Gurturk, A. Tezcaner, A. D. Dalgic, S. Korkmaz and D. Keskin, Med. Chem. Commun., 2017, 8, 1337
    DOI: 10.1039/C7MD00045F

Search articles by author

Spotlight

Advertisements